SCHEMBL1360468

SCHEMBL1360468

CC1(C)OB(c2cccnc2Oc2ccccc2)OC1(C)C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.44
LIPE Q05469 5/20 0.42
ALDH1A1 P00352 3/20 0.40
HTR1A P08908 1/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
LPL P06858 1/20 0.39
LIPG Q9Y5X9 1/20 0.39
MAPK8 P45983 2/20 0.39
ELANE P08246 2/20 0.39
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
HPGD P15428 1/20 0.37
DGAT1 O75907 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31395494 0.87 LIPE (0.42) LIPELPLLIPGKMT2AMEN1
SCHEMBL580807 0.87 MEN1 (0.45) TDP1LIPEALDH1A1KMT2AMEN1
SCHEMBL25426624 0.85 LIPE (0.55) LIPEALDH1A1
SCHEMBL25976343 0.84 LIPE (0.40) LIPEKMT2AMEN1DGAT1L3MBTL1
SCHEMBL25955360 0.84 LIPE (0.40) TDP1LIPEALDH1A1KMT2AMEN1
SCHEMBL25340238 0.84 LIPE (0.40) TDP1LIPEALDH1A1KMT2AMEN1
SCHEMBL30292561 0.83 APLNR (0.38) TDP1LIPELPLLIPG
SCHEMBL1484864 0.83 APLNR (0.38) TDP1LIPELPLLIPG
SCHEMBL22052722 0.82 LIPE (0.36) LIPELPLLIPGKMT2AMEN1
Water SCHEMBL2513501 0.81 APLNR (0.37) TDP1LIPELPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP disclosed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US disclosed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B TDP1 2980/4885LIPE 2694/4885ALDH1A1 861/4885
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS TDP1 3688/4885LIPE 2516/4885ALDH1A1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.